The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial
Open accessAbstract
Objective: To evaluate the effects of therapeutic heparin compared with prophylactic heparin among moderately ill patients with covid-19 admitted to hospital wards. Design: Randomised controlled, adaptive, open label clinical trial. Setting: 28 hospitals in Brazil, Canada, Ireland, Saudi Arabia, United Arab Emirates, and US. Participants: 465 adults admitted to hospital wards with covid-19 and increased D-dimer levels were recruited between 29 May 2020 and 12 April 2021 and were randomly assigned to therapeutic dose heparin (n=228) or prophylactic dose heparin (n=237). Interventions: Therapeutic dose or prophylactic dose heparin (low molecular weight or unfractionated heparin), to be continued until hospital discharge, day 28, or death. Main outcome measures: The primary outcome was a composite of death, invasive mechanical ventilation, non-invasive mechanical ventilation, or admission to an intensive care unit, assessed up to 28 days. The secondary outcomes included all cause death, the composite of all cause death or any mechanical ventilation, and venous thromboembolism. Safety outcomes included major bleeding. Outcomes were blindly adjudicated. Results: The mean age of participants was 60 years; 264 (56.8%) were men and the mean body mass index was 30.3 kg/m 2 . At 28 days, the primary composite outcome had occurred in 37/228 patients (16.2%) assigned to therapeutic heparin and 52/237 (21.9%) assigned to prophylactic heparin (odds ratio 0.69, 95% confidence interval 0.43 to 1.10; P=0.12). Deaths occurred in four patients (1.8%) assigned to therapeutic heparin and 18 patients (7.6%) assigned to prophylactic heparin (0.22, 0.07 to 0.65; P=0.006). The composite of all cause death or any mechanical ventilation occurred in 23 patients (10.1%) assigned to therapeutic heparin and 38 (16.0%) assigned to prophylactic heparin (0.59, 0.34 to 1.02; P=0.06). Venous thromboembolism occurred in two patients (0.9%) assigned to therapeutic heparin and six (2.5%) assigned to prophylactic heparin (0.34, 0.07 to 1.71; P=0.19). Major bleeding occurred in two patients (0.9%) assigned to therapeutic heparin and four (1.7%) assigned to prophylactic heparin (0.52, 0.09 to 2.85; P=0.69). Conclusions: In moderately ill patients with covid-19 and increased D-dimer levels admitted to hospital wards, therapeutic heparin was not significantly associated with a reduction in the primary outcome but the odds of death at 28 days was decreased. The risk of major bleeding appeared low in this trial. Trial registration: ClinicalTrials.gov NCT04362085 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Tang, N., Li, D., Wang, X., & Sun, Z. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14768 · Cited by 5,662
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Tang, N., Bai, H., Chen, X., Gong, J., Li, D., & Sun, Z. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14817 · Cited by 3,559
Assessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309
Self-citationPetrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., Tobin, K. A., Cerfolio, R. J., Francois, F., & Horwitz, L. I. (2020) · BMJ · doi:10.1136/bmj.m1966 · Cited by 3,054
CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis), Helms, J., Tacquard, C., Severac, F., Leonard-Lorant, I., Ohana, M., Delabranche, X., Merdji, H., Clere-Jehl, R., Schenck, M., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06062-x · Cited by 2,792
Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
WHO Solidarity Trial Consortium (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2023184 · Cited by 2,745
Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study
Wichmann, D., Sperhake, J.-P., Lütgehetmann, M., Steurer, S., Edler, C., Heinemann, A., Heinrich, F., Mushumba, H., Kniep, I., Schröder, A. S., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-2003 · Cited by 2,274
Interleukin-6 receptor antagonists in critically ill patients with Covid-19.
The REMAP-CAP Investigators (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100433 · Cited by 1,962
Self-citationIncidence of venous thromboembolism in hospitalized patients with COVID‐19
Middeldorp, S., Coppens, M., van Haaps, T. F., Foppen, M., Vlaar, A. P., Müller, M. C. A., Bouman, C. C. S., Beenen, L. F. M., Kootte, R. S., Heijmans, J., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14888 · Cited by 1,447
Self-citationTherapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
The ATTACC, A.-4. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105911 · Cited by 1,046
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
The REMAP-CAP, A.-4. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103417 · Cited by 941
Paranjpe, I., Fuster, V., Lala, A., Russak, A. J., Glicksberg, B. S., Levin, M. A., Charney, A. W., Narula, J., Fayad, Z. A., Bagiella, E., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.001 · Cited by 920
Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia
McGonagle, D., O'Donnell, J. S., Sharif, K., Emery, P., & Bridgewood, C. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30121-1 · Cited by 824
Schünemann, H. J., Cushman, M., Burnett, A. E., Kahn, S. R., Beyer-Westendorf, J., Spencer, F. A., Rezende, S. M., Zakai, N. A., Bauer, K. A., Dentali, F., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018022954 · Cited by 819
Self-citationAutopsy Findings and Venous Thromboembolism in Patients With COVID-19
Wichmann, D. (2020) · Annals of Internal Medicine · doi:10.7326/l20-1206 · Cited by 627
INSPIRATION Investigators, Mazloomzadeh, S., Khaleghparast, S., Ghadrdoost, B., Mousavizadeh, M., Baay, M. R., Noohi, F., Sharifnia, H., Ahmadi, A., Tavan, S., et al. (2021) · JAMA · doi:10.1001/jama.2021.4152 · Cited by 625
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler, P. R., Goligher, E. C., Berger, J. S., Neal, M. D., McVerry, B. J., Nicolau, J. C., Gong, M. N., et al. (n.d.) · Bern Open Repository and Information System (University of Bern) · doi:10.17863/cam.76384 · Cited by 581
Self-citationCoagulopathy of Coronavirus Disease 2019
Iba, T., Levy, J. H., Levi, M., Connors, J. M., & Thachil, J. (2020) · Critical Care Medicine · doi:10.1097/ccm.0000000000004458 · Cited by 534
Risk of venous thromboembolism in patients with COVID‐19: A systematic review and meta‐analysis
Nopp, S., Moik, F., Jilma, B., Pabinger, I., & Ay, C. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12439 · Cited by 489
Lopes, R. D., de Barros e Silva, P. G. M., Furtado, R. H. M., Macedo, A. V. S., Bronhara, B., Damiani, L. P., Barbosa, L. M., de Aveiro Morata, J., Ramacciotti, E., de Aquino Martins, P., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01203-4 · Cited by 481
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19
Talasaz, A. H., Sadeghipour, P., Kakavand, H., Aghakouchakzadeh, M., Kordzadeh-Kermani, E., Van Tassell, B. W., Gheymati, A., Ariannejad, H., Hosseini, S. H., Jamalkhani, S., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.035 · Cited by 184
Self-citationDoi, S. A., Furuya-Kanamori, L., Xu, C., Lin, L., Chivese, T., & Thalib, L. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.08.019 · Cited by 150
Wang, C., Chi, C., Guo, L., Wang, X., Guo, L., Sun, J., Sun, B., Liu, S., Chang, X., & Li, E. (2014) · Critical Care · doi:10.1186/s13054-014-0563-4 · Cited by 129
A proposal for staging COVID‐19 coagulopathy
Thachil, J. V., Cushman, M., Srivastava, A., & Angchaisuksiri, P. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12372 · Cited by 121
Self-citationTritschler, T., Mathieu, M., Skeith, L., Rodger, M. A., Middeldorp, S., Brighton, T., Sandset, P. M., Kahn, S. R., Angus, D., Blondon, M., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15094 · Cited by 97
Self-citationHeparin Therapy Improving Hypoxia in COVID-19 Patients – A Case Series
Negri, E. M., Piloto, B. M., Morinaga, L. T. K., Jardim, C., Lamy, S. A. E.-D., Ferreira, M. A., D’Amico, É. A., & Deheinzelin, D. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.573044 · Cited by 95
Self-citationHeparin and Related Drugs: Beyond Anticoagulant Activity
Page, C. P. (2013) · ISRN Pharmacology · doi:10.1155/2013/910743 · Cited by 87
Using heparin molecules to manage COVID‐2019
Liu, J., Li, J., Arnold, K., et al. (2020) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12353 · Cited by 79
Houston, B. L., Lawler, P. R., Goligher, E. C., Farkouh, M. E., Bradbury, C. A., Carrier, M., Džavík, V., Fergusson, D. A., Fowler, R., Galanaud, J. ‐., et al. (2020) · Clinical Trials · doi:10.1177/1740774520943846 · Cited by 65
Self-citationMu, S., Liu, Y., Jiang, J. H., Ding, R., Xu, L., Li, X., & Ma, X. (2018) · Respiratory Research · doi:10.1186/s12931-018-0925-6 · Cited by 54
Cited by
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus
Raman, B., Bluemke, D. A., Lüscher, T. F., & Neubauer, S. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac031 · Cited by 650
Spyropoulos, A. C., Goldin, M., Giannis, D., Diab, W., Wang, J., Khanijo, S., Mignatti, A., Gianos, E., Cohen, M., Sharifova, G., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.6203 · Cited by 461
Xu, S.-W., Ilyas, I., & Weng, J.-P. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00998-0 · Cited by 440
Henderson, L. A., Canna, S. W., Friedman, K. G., Gorelik, M., Lapidus, S. K., Bassiri, H., Behrens, E. M., Kernan, K. F., Schulert, G. S., Seo, P., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42062 · Cited by 296
Gorog, D. A., Storey, R. F., Gurbel, P. A., Tantry, U. S., Berger, J. S., Chan, M. Y., Duerschmied, D., Smyth, S. S., Parker, W. A. E., Ajjan, R. A., et al. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00665-7 · Cited by 286
Metadata
- Authors
- Sholzberg, M., Tang, G. H., Rahhal, H., AlHamzah, M., Kreuziger, L. B., Áinle, F. N., Alomran, F., Alayed, K., Alsheef, M., AlSumait, F., Pompilio, C. E., Sperlich, C., Tangri, S., Tang, T., Jaksa, P., Suryanarayan, D., Almarshoodi, M., Castellucci, L. A., James, P. D., Lillicrap, D., Carrier, M., Beckett, A., Colovos, C., Jayakar, J., Arsenault, M.-P., Wu, C., Doyon, K., Andreou, E. R., Dounaevskaia, V., Tseng, E. K., Lim, G., Fralick, M., Middeldorp, S., Lee, A. Y. Y., Zuo, F., da Costa, B. R., Thorpe, K. E., Negri, E. M., Cushman, M., & Jüni, P.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2021-10-14
- Volume
- 375
- Pages
- n2400
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W3205387447
- Cited by
- 380
- References
- 36
- FWCI
- 26.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.